Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders

Author(s): Wei-Yi Ong, Suku-Maran Shalini and Luca Costantino

Volume 21 , Issue 37 , 2014

Page: [4247 - 4256] Pages: 10

DOI: 10.2174/0929867321666140716103130

Price: $65

Abstract

Many potential drugs for the treatment of neurological diseases are unable to reach the brain in sufficient enough concentrations to be therapeutic because of the blood brain barrier. On the other hand, direct delivery of drugs to the brain provides the possibility of a greater therapeutic-toxic ratio than with systemic drug delivery. The use of intranasal delivery of therapeutic agents to the brain provides a means of bypassing the blood brain barrier in a non-invasive manner. In this respect, nanosized drug carriers were shown to enhance the delivery of drugs to CNS compared to equivalent drug solution formulations. Neurological conditions that have been studied in animal models that could benefit from nose-to-brain delivery of nanotherapeutics include pain, epilepsy, neurodegenerative disease and infectious diseases. The delivery of drugs to the brain via the nose-to-brain route holds great promise, on the basis of preclinical research by means of drug delivery systems such as polymeric nanoparticles and clinical data related to intranasal delivery to CNS of large molecular weight biologics administered in solution, but safety issues about toxicity on nasal mucosa, Np transport into the brain, delivery only to specific brain regions and variability in the adsorbed dose still represent research topics that need to be considered, with a view of clinical translation of these delivery systems.

Keywords: Blood brain barrier (BBB), nanomedicine, nanoparticles, neurological disorders, nose-to-brain, olfactory nerve.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy